Figure 1

Salinomycin treatment effectively hampers migration in cancer cells. A) Boyden chamber migration assays of different cancer cell lines during treatment. MDA-MB-436, LLC and 4T1-luc cells were treated for 18 h with 10 μM, 0.5 μM and 0.5 μM doxorubicin or 0.05 μM, 0.5 μM and 0.05 μM salinomycin, respectively. The number of migrated mock-treated (control) cells was set to 100%. (Student’s t-test, two-tailed, *p < 0.05; **p < 0.01). B) Cell viability upon doxorubicin or salinomycin treatment. MDA-MB-436, LLC and 4T1-luc cells were treated for 18 h with afore mentioned concentrations of doxorubicin or salinomycin. Cell viability was determined by a CellTiter Glo assay and normalized to mock-treated control cells. C) Boyden chamber migration assays of primary colon cancer cells. COGA2 and COGA10 cells were treated for 18 h with either doxorubicin (10 μM and 10 μM, respectively) or salinomycin (2.5 μM and 5 μM, respectively). The number of migrated mock-treated (control) cells was set to 100%. (Student’s t-test, two-tailed, salinomycin compared to control; *p < 0.05). D) Cell viability upon doxorubicin or salinomycin treatment. COGA2 and COGA10 cells were treated for 18 h with afore mentioned concentrations of doxorubicin or salinomycin. Cell viability was determined by a CellTiter Glo assay and normalized to mock-treated control cells.